Browse > Article

An Association between Liver Markers and Physiological Variables: Comparison between Normal and Fatty Liver Subjects  

Hyun, Kyung-Yae (Department of Clinical Labortory Science, College of Natural Sciences, Dong-Eui University)
Publication Information
Biomedical Science Letters / v.17, no.2, 2011 , pp. 105-112 More about this Journal
Abstract
We evaluated whether liver markers such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyltranspeptidase (GGT), and bilirubin have a relationship with other physiological factors in the normal (n=115) and fatty liver subjects (n=122) and there are differences between the two populations. Body indices were higher in the fatty liver group than in the normal group. Liver markers and blood pressure (BP) were greater in the fatty liver group than in the normal group. AST and ALT levels were positively correlated with body indices in the fatty liver group, but not in the normal group. AST, ALT and GGT levels in the fatty liver group had positive relationship with cardiovascular indices (CI). ALP and bilirubin levels were negatively associated with some of CI. Liver markers were negatively or positively correlated with inflammatory markers, thyroid hormones, or several biochemical markers levels. These findings suggest that abnormal changes in liver markers may be useful tool for diagnosis or prognosis of development of cardiovascular and/or inflammatory diseases as well as metabolic syndrome.
Keywords
Liver markers; Fatty liver; Body indices; Cardiovascular indices; Physiological variables;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Mason JE, Starke RD, Van Kirk JE. Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Prev Cardiol. 2010. 13: 36-41.   DOI   ScienceOn
2 Reaven GM. Role of insulin resistance in human disease. Banting Lecture. 1988. 37: 1595-1607.
3 Samanc H, Stojic V, Kirovski D, Jovanovic M, Cernescu H, Vujanac I. Thyroid Hormones Concentrations during the Mid-Dry Period: An Early Indicator of Fatty Liver in Holstein-Friesian Dairy Cows. J Thyroid Res. 2010. 2010: 1-6.
4 Schindhelm RK, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ, Diamant M. Alanine aminotransferase and the 6-year risk of the metabolic syndrome in Caucasian men and women: the Hoorn Study. Diabet Med. 2007. 24: 430-435.   DOI   ScienceOn
5 Sidorenkov O, Nilssen O, Grjibovski AM. Metabolic syndrome in Russian adults: associated factors and mortality from cardiovascular diseases and all causes. BMC Public Health. 2010. 10: 582-577.   DOI
6 Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006. 47: 51-59.   DOI   ScienceOn
7 Tagami T, Kimura H, Ohtani S, Tanaka T, Tanaka T, Hata S, Saito M, Miyazaki Y, Araki R, Tanaka M, Yonezawa K, Sawamura M, Ise T, Ogo A, Shimbo T, Shimatsu A, Naruse M. Multicenter study on the prevalence of hypothyroidism in patients with hypercholesterolemia. Endo Cr J. 2011. 10: 1-7.
8 Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007. 27: 435-440.   DOI   ScienceOn
9 Tuttle KR, Short RA, Johnson RJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol. 2001. 87: 1411-1414.   DOI   ScienceOn
10 Choi SC, Cho BK, Lee YH, Chang KS. Preoperative levels of hematological and biochemical indices affect perioperative variables in adult patients with coronary artery bypass graft surgery. J Exp Bio Sci. 2010. 16: 150-158.
11 Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003. 98: 960-967.   DOI   ScienceOn
12 Ghem CR, Sarmento-Leite E, de Quadros AS, Rossetto S, Gottschall CA. Serum bilirubin concentration in patients with an established coronary artery disease. Int Heart J. 2010. 51: 86-91.   DOI   ScienceOn
13 Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998. 27: 273-278.   DOI   ScienceOn
14 Ford ES, Li C, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation. 2007. 115: 2526-2532.   DOI   ScienceOn
15 Galvan AQ, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, Ferrannini E. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995. 268: E1-E5.
16 Hillbom M, Saloheimo P, Juvela S. Alcohol consumption, blood pressure, and the risk of stroke. Curr Hypertens Rep. 2011 3: 208-213.
17 Iacobellis G, Pellicelli AM, Grisorio B, Barbarini G, Leonetti F, Sharma AM, Barbaro G. Relation of epicardial fat and alanine aminotransferase in subjects with increased visceral fat. Obesity. 2008. 16: 179-183.   DOI   ScienceOn
18 Ji HF, Shen L. Uric acid potentially links fatty liver and high blood pressure. Hepatology. 2010 4: 1518-1519.
19 Kim HC, Choi KS, Jang YH, Shin HW DJ, Kim ES. Normal serum aminotransferase levels and the metabolic syndrome: Korean National Health and Nutrition Examination Surveys. Yonsei Med J. 2006. 47: 542-550.   DOI   ScienceOn
20 Kshatriya S, Liu K, Salah A, Szombathy T, Freeman RH, Reams GP, Spear RM, Villarreal D. Obesity hypertension: the regulatory role of leptin. Int J Hypertens. 2011. 2011: 1-8.
21 Liu MH, Yan M, Gao X, Gao J. Association of abnormality of liver enzymes and metabolic syndrome in patients with nonalcoholic fatty liver disease. Zhonghua Yi Xue Za Zhi. 2007. 87: 253-255.
22 Martins MC, Faleiro LL, Afonso B, Fonseca A. Association of gamma glutamyltransferase, metabolic syndrome and cardiovascular risk. Acta Med Port. 2010. 23: 579-588.
23 Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966. 275: 457-464.   DOI   ScienceOn
24 Babali A, Cakal E, Purnak T, Bıyıkoglu I, Cakal B, Yuksel O, Koklu S. Serum alpha-fetoprotein levels in liver steatosis. Hepatol Int. 2009. (in press)
25 Baou K, Vlachopoulos C, Manesis E, Archimandritis A, Stefanadis C. Non-alcoholic fatty liver and cardiovascular disease: an emerging relationship. Hellenic J Cardiol. 2007. 1: 37-41.
26 Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 2009. 7: 539-564.